Target v. Cordis/SciMed: ruling on implementation of preliminary injunction expected May 21.
This article was originally published in The Gray Sheet
Executive SummarySCIMED/CORDIS MOTION TO CONTINUE STAY ON GUIDEWIRE/MICROCATHETER preliminary injunction will be reviewed by Judge Robert Aguilar, U.S. District Court in San Francisco, at a May 21 hearing. On May 2, Aguilar granted Target Therapeutics' motion to impose a preliminary injunction prohibiting Cordis and SciMed from selling certain microcatheter and guidewire products. However, he also placed a temporary stay on the injunction pending the upcoming hearing.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.